Results 121 to 130 of about 42,031 (222)

Clinical results with the 31 mm CoreValve™ in large aortic annuli: The importance of implantation technique [PDF]

open access: yes, 2015
The CoreValve Revalving System (CRS) (Medtronic Inc., Minneapolis, MN, USA) is currently available in four sizes: 23 mm, 26 mm, 29 mm and 31 mm.
Cammalleri, V   +9 more
core   +1 more source

Emergency PCI and TAVR for Acute Myocardial Infarction in Severe Aortic Stenosis Patients

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Transcatheter aortic valve replacement (TAVR) is a viable alternative for patients with symptomatic severe aortic stenosis. Acute myocardial infarction is a contraindication to TAVR. The efficacy of emergency TAVR combined with percutaneous coronary intervention for patients presenting with acute myocardial infarction, severe aortic stenosis ...
Ruiyuan Lin   +9 more
wiley   +1 more source

Transcatheter Aortic Valve Replacement in Congenital Heart Disease

open access: yesJACC: Case Reports
Transcatheter aortic valve replacement is not widely used in patients with congenital heart disease. We describe our single-center experience of transcatheter aortic valve replacement in congenital heart disease, demonstrating short-term feasibility and ...
Betemariam Sharew, MS   +13 more
doaj   +1 more source

Characteristics of disruptive innovation within the medical device industry [PDF]

open access: yes, 2011
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2011.Cataloged from PDF version of thesis.Includes bibliographical references (p. 59-61).Innovation within the medical device industry had led to tremendous advances in the provision ...
Berlin, David B. (David Benjamin)
core  

Optimization of a transcatheter heart valve frame using patient-specific computer simulation

open access: yes, 2019
Purpose This study proposes a new framework to optimize the design of a transcatheter aortic valve through patient-specific finite element and fluid dynamics simulation.
De Beule, Matthieu   +5 more
core   +1 more source

DOAC Score Versus HAS‐BLED and ORBIT for Predicting Bleeding Events in Atrial Fibrillation on Direct Oral Anticoagulants

open access: yesClinical Cardiology, Volume 49, Issue 5, May 2026.
ABSTRACT Background The comparative performance of the DOAC score versus established bleeding risk scores in patients with atrial fibrillation (AF) receiving direct oral anticoagulants (DOACs) remains uncertain. This meta‐analysis evaluated the predictive ability of the DOAC score compared with HAS‐BLED and ORBIT.
Yanfei Guo, Wengen Zhu, Qunfeng Ren
wiley   +1 more source

Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB

open access: yesJIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Mucopolysaccharidosis Type IV is a multisystem lysosomal storage disease characterized by severe skeletal dysplasia resulting from impaired degradation of the glycosaminoglycans keratan sulfate and chondroitin‐6‐sulfate. The condition is classified into Types A and B based on the underlying enzyme deficiency.
Mark Wijnen   +5 more
wiley   +1 more source

A Descriptive Qualitative Study of Patient and Carer Perspectives on the Acceptability of Transcatheter Aortic Valve Implantation

open access: yesJournal of Advanced Nursing, Volume 82, Issue 5, Page 5305-5318, May 2026.
ABSTRACT Aim To provide a structured analysis of the acceptability of transcatheter aortic valve implantation to support clinical conversations, decision making and recovery for older adults with aortic stenosis and their carers. Background While transcatheter aortic valve implantation is an effective treatment for heart valve disease, its ...
Nicola Straiton   +2 more
wiley   +1 more source

Transcatheter Aortic Valve Replacement: The Experience of One Brazilian Health Care Center

open access: yesBrazilian Journal of Cardiovascular Surgery
Objective: Transcatheter aortic valve replacement has been an alternative to invasive treatment for symptomatic severe aortic stenosis in high risk patients. The primary endpoint was 30-day and 1-year mortality from any cause. Secondary endpoints were to
Fabiula Schwartz Azevedo   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy